fludarabine has been researched along with Primary Myelofibrosis in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 10 (38.46) | 24.3611 |
| 2020's | 7 (26.92) | 2.80 |
| Authors | Studies |
|---|---|
| Babushok, DV; Frey, NV; Freyer, CW; Gill, SI; Hexner, EO; Loren, AW; Luger, SM; Maity, A; Martin, ME; Plastaras, JP; Porter, DL | 1 |
| Alousi, AM; Bashir, Q; Champlin, RE; Hosing, C; Joseph, J; Kebriaei, P; Milton, DR; Olson, AL; Oran, B; Popat, UR; Qazilbash, MH; Ramdial, JL; Saini, NY; Shpall, EJ; Srour, SA | 1 |
| Czyż, A; Danylesko, I; Fein, JA; Nagler, A; Shem Tov, N; Shimoni, A; Shouval, R; Sobas, M; Vega, Y; Yerushalmi, R | 1 |
| Chhabra, S; D'Souza, A; Dhakal, B; Drobyski, WR; Fenske, TS; George, G; Hamadani, M; Hari, PN; Jerkins, JH; Michaelis, LC; Narra, RK; Pasquini, MC; Rizzo, RD; Saber, W; Shah, NN; Shaw, BE; Szabo, A; Wu, R | 1 |
| Banet, A; Battipaglia, G; Belhocine, R; Bianchessi, A; Bonnin, A; Boussaroque, A; Brissot, E; Duléry, R; Favale, F; Hirsch, P; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Memoli, M; Mohty, M; Paviglianiti, A; Sestili, S; Van de Wyngaert, Z; Vekhoff, A | 1 |
| Angelucci, E; Beauvais, D; Beelen, D; Bornhäuser, M; Castagna, L; Chevallier, P; Czerw, T; de Wreede, L; Finke, J; Hayden, P; Helbig, G; Hernández-Boluda, JC; Karakasis, D; Kröger, N; Maertens, J; Mauff, K; McLornan, D; Mear, JB; Mohty, M; Passweg, J; Polverelli, N; Reményi, P; Rifòn, J; Robin, M; Rubio, MT; Russo, D; Sirait, T; Vrhovac, R; Yakoub-Agha, I | 1 |
| Angelucci, E; Arcese, W; Battipaglia, G; Blaise, D; Chalandon, Y; Chiusolo, P; Contentin, N; Czerw, T; de Wreede, LC; Fanin, R; Fox, ML; Hayden, P; Hernandez-Boluda, JC; Iori, AP; Kroger, N; Marotta, G; Mauff, K; McLornan, D; Mohty, M; Pioltelli, P; Rubio, MT; Santarone, S; Sever, M; Solano, C; Wendel, L; Yakoub-Agha, I | 1 |
| Fauble, V; Hogan, WJ; Jain, T; Khera, N; Kunze, KL; Leis, JF; Mesa, RA; Noel, P; Palmer, J; Partain, DK; Patnaik, MS; Roy, V; Slack, JL; Sproat, LZ; Temkit, M | 1 |
| Alessandrino, EP; Bacigalupo, A; Bonifazi, F; Bosi, A; Bregante, S; Bruno, B; Carella, AM; Fanin, R; Finazzi, MC; Mammoliti, S; Masciulli, A; Messina, G; Milone, G; Narni, F; Patriarca, F; Pavoni, C; Rambaldi, A; Russo, D | 1 |
| Andreasson, B; Bacigalupo, A; Barosi, G; Boyer, M; Goldberg, JD; Gupta, V; Hoffman, R; Isola, L; Klisovic, RB; Marchioli, R; Mascarenhas, J; Miller, C; Najfeld, V; Orazi, A; Prchal, JT; Price, LS; Prosperini, G; Rambaldi, A; Rondelli, D; Scarano, M; Shore, TB; Silverman, LR; Vannucchi, AM; Weinberg, RS; Wetzler, M | 1 |
| Alam, N; Atenafu, EG; Gupta, V; Kim, DH; Kuruvilla, J; Lipton, JH; Messner, HA; Seftel, M; Shanavas, M; Uhm, J | 1 |
| Assanelli, A; Bernardi, M; Carrabba, M; Ciceri, F; Claudiani, S; Corti, C; De Freitas, T; Giglio, F; Guggiari, E; Lunghi, F; Lupo-Stanghellini, MT; Marcatti, M; Marktel, S; Peccatori, J; Piemontese, S | 1 |
| Broers, AE; Janssen, JJ; Raymakers, R; Slot, S; Smits, K; Te Boekhorst, PA; van de Donk, NW; Witte, BI; Zweegman, S | 1 |
| Alchalby, H; Ayuk, F; Cassinat, B; Christopeit, M; Kröger, N; Peffault de Latour, R; Porcher, R; Robin, M; Sicre de Fontbrune, F; Socié, G; Wolschke, C; Zabelina, T | 1 |
| Baurmann, H; Bethge, W; Bornhäuser, M; Brand, R; Burchert, A; Corradini, P; de Witte, TM; Dreger, P; Einsele, H; Holler, E; Kaufmann, M; Kobbe, G; Kröger, N; Kvasnicka, HM; Nagler, A; Niederwieser, D; Schubert, J; Schwerdtfeger, R; Stelljes, M; Thiele, J; Uharek, L; Wandt, H; Wulf, GG; Zabelina, T; Zander, AR | 1 |
| HANDA, H; KARASAWA, M; MATSUSHIMA, T; MAWATARI, M; MURAKAMI, H; NOJIMA, Y; OSAKI, Y; SAITOH, T; SEKIGAMI, T; TAHARA, K; TOYAMA, K; TSUKAMOTO, N; UCHIUMI, H; YOKOHAMA, A | 1 |
| Asano-Mori, Y; Ishiwata, K; Masuoka, K; Matsuno, N; Miyakoshi, S; Ohashi, K; Ota, Y; Takagi, S; Takahashi, K; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, H | 1 |
| Anasetti, C; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Komrokji, RS; Nishihori, T; Perkins, J; Pidala, J; Roman-Diaz, J | 1 |
| Abdullah, A; Ho, AY; Kenyon, M; Krishnamurthy, P; Lea, N; Lim, ZY; Marsh, J; Mufti, GJ; Nagi, W; Pagliuca, A; Potter, V; Reiff-Zall, L; Tindell, V | 1 |
| Ayuk, FA; Erttmann, R; Hansen, A; Hessling, J; Kordes, U; Kröger, N; Panse, J; Renges, H; Werner, M; Zabelina, T; Zander, AR | 1 |
| Disel, U; Ergin, M; Paydas, S; Yavuz, S | 1 |
| Ayuk, F; Fehse, B; Fehse, N; Kröger, N; Kvasnicka, HM; Panse, J; Schieder, H; Stute, N; Thiele, J; Waschke, O; Zabelina, T; Zander, A | 1 |
| Andreasson, B; Birgegård, G; Brune, M; Kutti, J; Lazarevic, V; LeBlanc, K; Malm, C; Merup, M; Nahi, H; Nilsson, L | 1 |
| Bethge, W; Bornhäuser, M; de Witte, T; Kobbe, G; Kröger, N; Kvasnicka, HM; Schubert, J; Schwerdtfeger, R; Thiele, J; Zander, A | 1 |
| Azaceta, G; Gutierrez, M; Palomera, L; Soria, J; Varo, MJ | 1 |
| Bradlow, BA; Chen, YH; Devine, SM; Hoffman, R; Huml, M; Jessop, E; Maynard, V; Peace, D; Shah, R; Stock, W; Thomason, D; van Besien, K; Verma, A | 1 |
7 trial(s) available for fludarabine and Primary Myelofibrosis
| Article | Year |
|---|---|
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EB
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Organ Size; Primary Myelofibrosis; Registries; Retrospective Studies; Spleen; Splenectomy; Survival Rate; Vidarabine | 2021 |
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.
Topics: Adult; Blood Donors; Busulfan; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Prognosis; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2019 |
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
Topics: Adult; Aged; Analysis of Variance; Antilymphocyte Serum; Blood Donors; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Janus Kinase 2; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Mutation; Primary Myelofibrosis; Prospective Studies; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2014 |
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Recurrence; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2009 |
Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis.
Topics: Aged; Busulfan; Cord Blood Stem Cell Transplantation; Feasibility Studies; Female; Graft Survival; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2010 |
Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Topics: Adult; Bone Marrow Examination; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Male; Middle Aged; Primary Myelofibrosis; Remission Induction; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Melphalan; Middle Aged; Primary Myelofibrosis; Splenomegaly; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
19 other study(ies) available for fludarabine and Primary Myelofibrosis
| Article | Year |
|---|---|
Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis.
Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Primary Myelofibrosis; Retrospective Studies; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2022 |
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning.
Topics: Busulfan; Graft vs Host Disease; Humans; Methotrexate; Primary Myelofibrosis; Recurrence; Tacrolimus | 2023 |
Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Transplantation Conditioning; Vidarabine | 2020 |
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Primary Myelofibrosis; Thiotepa; Transplantation Conditioning; Vidarabine | 2021 |
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasms; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2021 |
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2019 |
Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis.
Topics: Aged; Allografts; Busulfan; Disease-Free Survival; Female; Humans; Male; Middle Aged; Primary Myelofibrosis; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2016 |
Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calreticulin; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease Progression; Female; Graft Survival; Humans; Janus Kinase 2; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutrophils; Peripheral Blood Stem Cell Transplantation; Polycythemia Vera; Primary Myelofibrosis; Receptors, Thrombopoietin; Retrospective Studies; Thrombocythemia, Essential; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2015 |
Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.
Topics: Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Recurrence; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
Successful treatment with reduced-intensity stem cell transplantation for secondary myelofibrosis following polycythemia vera.
Topics: Female; Graft vs Host Disease; Humans; Janus Kinase 2; Melphalan; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2009 |
Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Retrospective Studies; Survival Rate; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2010 |
Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Primary Myelofibrosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2011 |
Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.
Topics: Adult; Busulfan; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Fludarabine as the possible cause of acute myelofibrosis.
Topics: Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Primary Myelofibrosis; Vidarabine | 2004 |
Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.
Topics: Adult; Antilymphocyte Serum; Blood Transfusion, Autologous; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Middle Aged; Pilot Projects; Primary Myelofibrosis; Prospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2005 |
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Middle Aged; Postoperative Complications; Primary Myelofibrosis; Spleen; Time Factors; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fatal Outcome; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pancytopenia; Prednisone; Primary Myelofibrosis; Vidarabine; Vincristine | 1998 |